Corcept Therapeutics Inc

CORT

Pharmaceutical Preparations

Mkt Cap

$2.596B

PE

28.57

Debt

Cash

$111.8M

EV

FCF

$154.4M

Market Cap

$2.596B

P/E Ratio

28.57

Debt

Cash

$111.8M

EV

FCF

$154.4M

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe metabolic, oncologic, endocrine, and neurological disorders in the United States. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. It is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Sector

10-Q
9/30/23
10-Q
6/30/23
10-Q
3/31/23
10-K
12/31/22
10-Q
9/30/22
10-Q
6/30/22
10-Q
3/31/22
10-K
12/31/21
10-Q
9/30/21
10-Q
6/30/21
10-Q
3/31/21
10-K
12/31/20
10-Q
9/30/20
10-Q
6/30/20
10-Q
3/31/20
10-K
12/31/19
10-Q
9/30/19
10-Q
6/30/19
10-Q
3/31/19
10-K
12/31/18
10-Q
9/30/18
10-Q
6/30/18
10-Q
3/31/18
10-K
12/31/17

DCF

Discounted Cash Flow Valuation of Corcept Therapeutics Inc

Calculate

Growth Years

Growth

Start

End

Discount

Start

End

Multiple

g\r	+10%	+11%	+12%	+13%	+14%
0%	10	9	8	8	7
+1%	11	10	9	8	8
+2%	13	11	10	9	8
+3%	14	13	11	10	9
+4%	17	14	12	11	10

Years	0	1	2	3	4	5	6	7	8	9	10	TV
FCF	$154.4M	$200.7M	$255.3M	$317.7M	$386.6M	$459.6M	$533.6M	$604.8M	$668.6M	$720.6M	$756.6M	$7.566B
DCF		$174.5M	$193.1M	$208.9M	$221M	$228.5M	$230.7M	$227.4M	$218.6M	$204.8M	$187M	$1.87B
Value	$3.965B

Chart P/E ratio

In the chart Earnings are multiplied by this value.

Earnings Growth 38%

Earnings Stability 23%

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

The Net Margin is high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Over time the ROA has been decreasing indicating a lower marginal ROA with respect to the calculated one, this could impede growth.

Years	12-2014	12-2015	12-2016	12-2017	12-2018	12-2019	12-2020	12-2021	12-2022	TTM
Net Margin	-120%	-13%	10%	81%	30%	31%	30%	31%	25%	20%
ROA	-80%	-6.6%	15%	24%	29%	28%	23%	29%	20%	19%
ROE	930%	-35%	20%	68%	27%	25%	20%	30%	20%	20%

What is the average Net Margin?

The average Net Margin over the past 5 years is +37.96%.

What is the trend of Net Margin?

The trend of Net Margin over the past 5 years is -7.95%.

What is the average Return on Assets (ROA)?

The average ROA over the past 5 years is +25.57%.

What is the trend of Return on Assets (ROA)?

The trend of ROA over the past 5 years is -0.66%.

What is the average Return on Equity (ROE)?

The average ROE over the past 5 years is +31.78%.

What is the trend of Return on Equity (ROE)?

The trend of ROE over the past 5 years is -6.7%.

Safety & Stabiliy

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Data are missing

The Graham’s stability indicate reliability of earnings, and consideration about the future are more dependable.

Years	12-2014	12-2015	12-2016	12-2017	12-2018	12-2019	12-2020	12-2021	12-2022	TTM
Debt FCF	-1.98	19.26	0.81	0.00	-	-	-	-	-	-
Debt Equity	-16.06	3.24	0.35	0.00	-	-	-	-	-	-
MIN
Graham Stability	-	-	-	-	100%	100%	100%	100%	97%	97%

What is the Debt/FCF?

The Debt/FCF trailing twelve month is -.

What is the trend of Debt/FCF?

The trend of Debt/FCF over the past 5 years is -.

What is the Graham’s Stability?

Graham’s Stability measure stands at 0.97.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Earnings growth has not been increasing in the past years.

Years	12-2015	12-2017	12-2019	12-2021	Trend
Revenue	35%	20%	9.5%	9.8%	-17%
Net Income	-	-4.7%	2.5%	-10%	-210%
Stockholders Equity	60%	21%	11%	34%	-38%
FCF	68%	15%	-3.9%	-28%	-74%

What is the 5 year Revenue CAGR?

The Revenue CAGR over the past 5 years is +20.34%.

What is the trend of Revenue growth?

The trend of Revenue growth rate over the past 5 years is -16.84%.

What is the 5 year Earnings CAGR?

The Earnings CAGR over the past 5 years is -4.74%.

What is the trend of Earnings growth?

The trend of Earnings growth rate over the past 5 years is -210.01%.

What is the 5 year Equity CAGR?

The Equity CAGR over the past 5 years is +21.32%.

What is the trend of Equity growth?

The trend of Equity growth rate over the past 5 years is -37.62%.

What is the 5 year FCF CAGR?

The FCF CAGR over the past 5 years is +14.66%.

What is the trend of FCF growth?

The trend of FCF growth rate over the past 5 years is -73.6%.